See more : Healthwell Acquisition Corp. I (HWEL) Income Statement Analysis – Financial Results
Complete financial analysis of Crossject Société Anonyme (ALCJ.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Crossject Société Anonyme, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Mineral Commodities Ltd (MRC.AX) Income Statement Analysis – Financial Results
- Luminar Technologies, Inc. (LAZR) Income Statement Analysis – Financial Results
- LG Display Co., Ltd. (LPL) Income Statement Analysis – Financial Results
- Sanrio Company, Ltd. (SNROF) Income Statement Analysis – Financial Results
- Bigblu Broadband plc (BBB.L) Income Statement Analysis – Financial Results
Crossject Société Anonyme (ALCJ.PA)
About Crossject Société Anonyme
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 145.00K | 954.00K | 912.00K | 4.84M | 500.00K | 2.44M | 3.23M | 1.42M | 1.59M | 1.39M | 935.92K | 353.50K | 650.00K | 200.00K |
| Cost of Revenue | 6.28M | 14.85M | 11.98M | 3.95M | 10.40M | 2.97M | 2.26M | 1.70M | 1.50M | 4.06M | 921.10K | 79.28K | 44.08K | 2.05M |
| Gross Profit | -6.14M | -13.89M | -11.06M | 894.74K | -9.90M | -523.83K | 975.68K | -282.04K | 89.16K | -2.67M | 14.82K | 274.22K | 605.92K | -1.85M |
| Gross Profit Ratio | -4,231.03% | -1,456.39% | -1,213.05% | 18.47% | -1,980.15% | -21.43% | 30.17% | -19.82% | 5.62% | -192.79% | 1.58% | 77.57% | 93.22% | -926.79% |
| Research & Development | 9.56M | 7.41M | 6.06M | 5.80M | 4.65M | 5.17M | 4.51M | 3.76M | 3.63M | 2.73M | 555.76K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -9.06M | -6.98M | -5.72M | 540.49K | -4.65M | 8.56M | 6.64M | 5.93M | 5.14M | 1.65M | 1.18M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 5.17M | 1.10M | -633.00K | -604.57K | 776.90K | -481.73K | -76.72K | -12.54K | 665.69K | 0.00 | 1.67M | -81.00 | 2.46M | 1.00 |
| Operating Expenses | 5.67M | -666.00K | 975.00K | 6.94M | -776.69K | 9.04M | 6.72M | 5.94M | 4.48M | 2.70M | 1.67M | 1.68M | 2.46M | 2.58M |
| Cost & Expenses | 11.95M | 14.18M | 12.95M | 10.89M | 9.62M | 12.01M | 8.98M | 7.64M | 5.97M | 6.75M | 2.59M | 1.76M | 2.50M | 4.63M |
| Interest Income | 0.00 | 40.00K | 19.00K | 41.63K | 43.83K | 222.64K | 17.53K | 37.71K | 18.89K | 61.25K | 195.54K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 497.00K | 277.00K | 845.00K | 408.17K | 98.61K | 222.64K | 17.53K | 37.71K | 18.89K | 36.42K | 195.54K | 212.42K | 318.42K | 341.80K |
| Depreciation & Amortization | 4.50M | 5.26M | 4.49M | 3.95M | 3.65M | 2.97M | 2.26M | 1.70M | 1.50M | 1.04M | 632.00K | 493.78K | 836.14K | 766.84K |
| EBITDA | -7.30M | -8.03M | -7.33M | -7.13M | -4.76M | -9.04M | -6.36M | -5.94M | -5.52M | -4.23M | -1.54M | -681.02K | -1.01M | -3.66M |
| EBITDA Ratio | -5,031.72% | -834.91% | -827.63% | -143.34% | -1,095.37% | -370.06% | -207.75% | -417.50% | -282.20% | -293.54% | -206.10% | -255.09% | -155.90% | -1,834.60% |
| Operating Income | -11.80M | -13.23M | -12.04M | -10.89M | -9.12M | -12.01M | -8.98M | -7.64M | -5.97M | -5.11M | -2.62M | -1.41M | -1.85M | -4.43M |
| Operating Income Ratio | -8,137.93% | -1,386.58% | -1,319.96% | -224.87% | -1,824.81% | -491.49% | -277.59% | -537.33% | -376.58% | -368.75% | -279.50% | -399.98% | -285.34% | -2,215.70% |
| Total Other Income/Expenses | 295.00K | -91.00K | -801.00K | -597.12K | 133.20K | -291.58K | 238.12K | -113.34K | -759.65K | -196.81K | 225.03K | 17.49K | 2.59M | -337.02K |
| Income Before Tax | -11.51M | -13.38M | -12.62M | -11.49M | -8.51M | -12.30M | -8.74M | -7.76M | -6.73M | -5.30M | -2.39M | -1.40M | 737.41K | -4.77M |
| Income Before Tax Ratio | -7,934.48% | -1,402.41% | -1,384.21% | -237.20% | -1,701.95% | -503.42% | -270.23% | -545.30% | -424.48% | -382.95% | -255.45% | -395.03% | 113.45% | -2,384.21% |
| Income Tax Expense | -2.87M | -2.22M | -1.82M | -1.65M | -1.34M | -1.59M | -1.13M | -1.10M | -1.05M | 968.40K | -568.28K | -470.68K | -807.95K | -1.12M |
| Net Income | -8.64M | -11.16M | -10.81M | -9.84M | -7.17M | -10.71M | -7.61M | -6.66M | -5.69M | -4.34M | -1.82M | -925.75K | 1.55M | -4.12M |
| Net Income Ratio | -5,957.24% | -1,169.50% | -1,184.87% | -203.22% | -1,434.74% | -438.26% | -235.32% | -468.32% | -358.57% | -313.04% | -194.74% | -261.88% | 237.75% | -2,058.76% |
| EPS | -0.23 | -0.31 | -0.42 | -0.41 | -0.36 | -0.79 | -0.83 | -0.88 | -0.81 | -0.65 | -0.34 | -0.21 | 0.35 | -0.93 |
| EPS Diluted | -0.23 | -0.31 | -0.42 | -0.41 | -0.36 | -0.79 | -0.83 | -0.88 | -0.74 | -0.65 | -0.34 | -0.21 | 0.35 | -0.93 |
| Weighted Avg Shares Out | 37.09M | 36.36M | 26.01M | 24.06M | 20.13M | 13.61M | 9.20M | 7.56M | 7.01M | 6.65M | 5.28M | 4.43M | 4.43M | 4.43M |
| Weighted Avg Shares Out (Dil) | 38.16M | 36.36M | 26.01M | 24.06M | 20.13M | 13.61M | 9.20M | 7.56M | 7.67M | 6.65M | 5.28M | 4.43M | 4.43M | 4.43M |
Source: https://incomestatements.info
Category: Stock Reports